Follow The Filings

HALO Halozyme Therapeutics

Health Care, filed as Halozyme Therapeutics (COM), Equity As of 2026 Q3 among managers we track Quote on Google Finance, opens in a new tab

  • 1 Owner
  • Max 0.6%
  • $4.3M
  • 1 reduce 1 exit

In 2026 Q3 Torray Investment Partners trimmed Halozyme Therapeutics, and Richard Pzena sold out.

Who owns this now

Largest portfolio weights among holders, up to 0.6% (Torray Investment Partners). Not free-float ownership.

  1. Torray Investment Partners Reduce 0.56%

Who owns HALO

Sorted by value, long equity only, as of 2026 Q3.

History
Torray Investment Partners 0.56% Reduce −0.4% 38,540 $4.3M History
Richard Pzena, Pzena Investment Management exited 2026 Q3 Last 2026 Q2 <0.01% Exit 0.00% 4,049 $317K History

1 current, 1 exited last period, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by HALO's executives, directors and 10% owners in the last 12 months, from their Form 4s

All HALO insider trades
  • None no insider bought on the open market
  • $2M sold by 1 insider outside a trading plan
  • $46.1M sold by 4 insiders under 10b5-1 plans
  1. Helen Torley CEO
    Planned sale
    $6.6M 60,000 shares at $110.18 7.2% of stake
    Traded Oct 6–8 Filed Oct 8
    ↗
  2. Matthew L. Posard Director
    Planned sale
    $568K 5,230 shares at $108.54 8.9% of stake
    Traded Oct 1 Filed Oct 2
    ↗
  3. Matthew L. Posard Director
    Planned sale
    $2M 18,996 shares at $107.74 24% of stake
    Traded Sep 16 Filed Sep 17
    ↗
  4. Helen Torley CEO
    Planned sale
    $6.4M 60,000 shares at $107.28 7.2% of stake
    Traded Sep 9–11 Filed Sep 11
    ↗
  5. Helen Torley CEO
    Planned sale
    $6.3M 60,000 shares at $104.59 7.2% of stake
    Traded Aug 17–19 Filed Aug 19
    ↗
  6. Bernadette Connaughton Director
    Planned sale
    $167K 1,626 shares at $102.80 3.9% of stake
    Traded Aug 10 Filed Aug 11
    ↗
  7. Helen Torley CEO
    Planned sale
    $153K 1,923 shares at $79.77 0.2% of stake
    Traded Jul 8 Filed Jul 9
    ↗
  8. Bernadette Connaughton Director
    Planned sale
    $125K 1,625 shares at $76.71 3.7% of stake
    Traded Jul 1 Filed Jul 2
    ↗
  9. Mahesh Krishnan Director
    Planned sale
    $548K 7,304 shares at $75.00 34% of stake
    Traded Jun 29 Filed Jun 30
    ↗
  10. Helen Torley CEO
    Planned sale
    $3.4M 50,000 shares at $67.40 6.1% of stake
    Traded Jun 1–3 Filed Jun 3
    ↗
  11. Bernadette Connaughton Director
    Planned sale
    $108K 1,625 shares at $66.21 3.6% of stake
    Traded Jun 1 Filed Jun 2
    ↗
  12. Helen Torley CEO
    Planned sale
    $3.4M 50,000 shares at $68.68 6.1% of stake
    Traded May 11–13 Filed May 13
    ↗
  13. Bernadette Connaughton Director
    Planned sale
    $103K 1,625 shares at $63.48 4.1% of stake
    Traded May 1 Filed May 5
    ↗
  14. Helen Torley CEO
    Planned sale
    $635K 10,000 shares at $63.50 1.3% of stake
    Traded Apr 6 Filed Apr 7
    ↗
  15. Helen Torley CEO
    Planned sale
    $2.6M 40,000 shares at $64.81 5% of stake
    Traded Apr 1–2 Filed Apr 2
    ↗

Also filed in the last 12 months, not counted as buying or selling: 51 option exercises, 18 share withholdings for taxes, 9 stock grants, 1 gift, and 1 sale to cover taxes.

Congress

2 members of Congress traded HALO in the last three years: 1 buy and 3 sales. 2 members listed it in 2025 annual reports.

All Congress trades
  1. Gilbert Ray Cisneros, Jr. D-CA-31 Partial sale $1K–$15K Sep 29 filed Oct 12
  2. Gilbert Ray Cisneros, Jr. D-CA-31 Buy $1K–$15K Mar 9 filed Apr 7
  3. Gilbert Ray Cisneros, Jr. D-CA-31 Partial sale $1K–$15K Mar 24, 2025 filed Apr 7, 2025
  4. Josh Gottheimer D-NJ-5Joint Partial sale $1K–$15K Sep 9, 2024 filed Oct 3, 2024

SEC filings

Recent issuer filings from EDGAR, 14 shown.

Filed Form Detail Links
8-K 5.02 Filing Doc
8-K 1.01,2.03,3.02,9.01 Filing Doc
8-K 8.01,9.01 Filing Doc
8-K 8.01,9.01 Filing Doc
8-K 5.02 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 5.02 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 5.07 Filing Doc
SCHEDULE 13G — Filing Doc
8-K 5.02,9.01 Filing Doc
8-K 5.03,9.01 Filing Doc

Source: SEC EDGAR submissions, updated 13 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $0.829B $1.02B $1.4B
Gross profit * $0.637B $0.856B $1.17B
Gross margin * 76.8% 84.3% 83.6%
Net income $281.59M $444.09M $316.89M
Net margin * 34.0% 43.7% 22.7%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $0.746B $1.09B $0.825B
Total non-current assets * $0.987B $0.978B $1.7B
Total assets $1.73B $2.06B $2.53B
Total current liabilities $112.49M $139.1M $177.09M
Total non-current liabilities * $1.54B $1.56B $2.3B
Total equity $83.81M $363.82M $48.81M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations $388.57M $479.06M $651.56M
Cash from investing -$96.91M -$262.72M -$545.81M
Cash from financing -$407.99M -$218.86M -$85.17M
Net change in cash -$116.32M -$2.52M $20.57M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.